DRAWBRIDGE SECURES FDA 510(K) CLEARANCE FOR AT-HOME BLOOD SAMPLING DEVICE NANODROP
Drawbridge Health, a healthcare technology company focused on reinventing the blood draw experience, today announced that its at-home, patented blood sampling device, NanoDrop, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Over-the-Counter use. The clearance of this…
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial, conducted on both healthy…
Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing
Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies is moving forward with its appetite suppression supplement, TPT0701. Modulation of the endocannabinoid system has long been recognized…
Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S.
Sigrid Therapeutics has launched the Glucose Stabiliser, an over-the-counter blood sugar control supplement that also reduces caloric intake from fats and carbs. With about 1 in every 10 Americans facing a Type 2 diagnosis and the growing popularity of medications used for…
